This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Urologists, Henry Schein Urge Families To Put A Prostate Cancer Check-up On The Back To School List For Dad

MELVILLE, N.Y., Sept. 18, 2013 /PRNewswire/ -- LUGPA, representing more than 2,000 urologists nationwide, and Henry Schein Cares, the global corporate social responsibility program of Henry Schein, Inc., have partnered again this year to raise awareness among families across the country of the importance of putting prostate cancer check-ups on the calendar for the men in their lives. September – for many families, back-to-school time for the kids – is Prostate Cancer Awareness Month. To create more public awareness about the importance of early detection of prostate cancer to save men's lives, LUGPA and Henry Schein have re-launched an educational initiative to put a prostate cancer check-up for dad on American families' back to school list.

(Photo: )

"Prostate cancer remains the second-leading cause of cancer death in American men. As children return to school this year, we want families to be reminded that with early detection, this disease is almost always curable," said Dr. Deepak A. Kapoor, a prominent New York urologist and president of LUGPA. "Take this opportunity to remind your loved ones to have a discussion with their doctor to determine if they need a prostate check-up. Together we can help ensure that generations of men are there to see their children and grandchildren, grow up and go back to school each year."

According to Dr. Kapoor, one out of six American men will have prostate cancer in their lifetime; the incidence is even higher for African-American men, those with a family history of prostate cancer and men with a higher baseline PSA in their 40s. Prostate cancer is the most common non-skin malignancy diagnosed in men; with early detection efforts, the death rate from prostate cancer has decreased by over 40 percent in the United States.

Dr. Kapoor stated, "The most recent PSA screening guidelines – released just last month – state definitively that PSA screening reduces cancer mortality and reduces the risk of being diagnosed with or developing advanced prostate cancer.  Furthermore, it is recommended that men between the ages of 40-45 obtain a baseline PSA, and that all men with a life expectancy of 10 years or more be screened, regardless of age." "Unfortunately, there are no symptoms during the early stages of prostate cancer, when the disease is most treatable," said Kapoor. "Despite improvement in patient education and awareness, many men still fall through the cracks. When the disease is caught early, the 10-year survival is almost 99 percent. We support the rights of men to access appropriate, life-saving prostate cancer screening, and we encourage men to have a conversation with their doctors regarding whether screening is appropriate for them."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs